DB15560InvestigationalProtein Based Therapies
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
- Code names
- ALLN-177
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Reloxaliase, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account